Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas.

Hilvo M, de Santiago I, Gopalacharyulu P, Schmitt WD, Budczies J, Kuhberg M, Dietel M, Aittokallio T, Markowetz F, Denkert C, Sehouli J, Frezza C, Darb-Esfahani S, Braicu EI.

Cancer Res. 2016 Feb 15;76(4):796-804. doi: 10.1158/0008-5472.CAN-15-2298. Epub 2015 Dec 18.

2.

The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.

Gayarre J, Kamieniak MM, Cazorla-Jiménez A, Muñoz-Repeto I, Borrego S, García-Donas J, Hernando S, Robles-Díaz L, García-Bueno JM, Ramón Y Cajal T, Hernández-Agudo E, Heredia Soto V, Márquez-Rodas I, Echarri MJ, Lacambra-Calvet C, Sáez R, Cusidó M, Redondo A, Paz-Ares L, Hardisson D, Mendiola M, Palacios J, Benítez J, García MJ.

J Gynecol Oncol. 2016 Jan;27(1):e7. doi: 10.3802/jgo.2016.27.e7. Epub 2015 Nov 27.

3.

Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.

Zhu CX, Xiong W, Wang ML, Yang J, Shi HJ, Chen HQ, Niu G.

J Int Med Res. 2018 Feb;46(2):723-731. doi: 10.1177/0300060517717625. Epub 2017 Sep 12.

4.

CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer.

Ye Y, Yin M, Huang B, Wang Y, Li X, Lou G.

Tumour Biol. 2015 Jun;36(6):4175-9. doi: 10.1007/s13277-015-3052-8. Epub 2015 Jan 13.

PMID:
25582317
5.

SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.

Yang M, Xie X, Ding Y.

Oncol Rep. 2016 Mar;35(3):1796-806. doi: 10.3892/or.2016.4545. Epub 2016 Jan 5.

PMID:
26750614
6.

Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites.

Feigenberg T, Clarke B, Virtanen C, Plotkin A, Letarte M, Rosen B, Bernardini MQ, Kollara A, Brown TJ, Murphy KJ.

Biomed Res Int. 2014;2014:367103. doi: 10.1155/2014/367103. Epub 2014 May 25.

7.

POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D.

Gynecol Oncol. 2014 Feb;132(2):334-42. doi: 10.1016/j.ygyno.2013.12.021. Epub 2013 Dec 22.

PMID:
24368280
8.

A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.

Jin C, Xue Y, Li Y, Bu H, Yu H, Zhang T, Zhang Z, Yan S, Lu N, Kong B.

Int J Gynecol Cancer. 2018 Jan;28(1):51-58. doi: 10.1097/IGC.0000000000001141.

PMID:
28976449
9.

Sox10 expression in ovarian epithelial tumors is associated with poor overall survival.

Kwon AY, Heo I, Lee HJ, Kim G, Kang H, Heo JH, Kim TH, An HJ.

Virchows Arch. 2016 May;468(5):597-605. doi: 10.1007/s00428-016-1918-9. Epub 2016 Mar 7.

PMID:
26951260
10.

Expression of BRAF V600E mutant protein in epithelial ovarian tumors.

Preusser M, Capper D, Berghoff AS, Horvat R, Wrba F, Schindl M, Schoppmann SF, von Deimling A, Birner P.

Appl Immunohistochem Mol Morphol. 2013 Mar;21(2):159-64. doi: 10.1097/PAI.0b013e31825d7402.

PMID:
22820660
11.

Intraoperative Diagnosis Support Tool for Serous Ovarian Tumors Based on Microarray Data Using Multicategory Machine Learning.

Park JS, Choi SB, Kim HJ, Cho NH, Kim SW, Kim YT, Nam EJ, Chung JW, Kim DW.

Int J Gynecol Cancer. 2016 Jan;26(1):104-13. doi: 10.1097/IGC.0000000000000566.

PMID:
26512784
12.

Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer.

De Donato M, Petrillo M, Martinelli E, Filippetti F, Zannoni GF, Scambia G, Gallo D.

Gynecol Oncol. 2017 Jul;146(1):170-178. doi: 10.1016/j.ygyno.2017.05.001. Epub 2017 May 9.

PMID:
28495238
13.

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.

Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piché A.

BMC Cancer. 2015 Jul 1;15:492. doi: 10.1186/s12885-015-1511-7.

14.

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.

Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson AM, Squire JA.

Br J Cancer. 2015 Mar 31;112(7):1215-22. doi: 10.1038/bjc.2015.81. Erratum in: Br J Cancer. 2015 Dec 22;113(12):1746. Masson, A-M M [corrected to Mes-Masson, A-M].

15.

Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.

Ricciardelli C, Lokman NA, Pyragius CE, Ween MP, Macpherson AM, Ruszkiewicz A, Hoffmann P, Oehler MK.

Oncotarget. 2017 Mar 14;8(11):17819-17832. doi: 10.18632/oncotarget.14867.

16.

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolniy F, Makker V, Sala E, Soumerai TE, Hyman DM, Socci ND, Viale A, Gershenson DM, Farley J, Levine DA, Rosen N, Berger MF, Spriggs DR, Aghajanian CA, Solit DB, Iyer G.

J Clin Oncol. 2015 Dec 1;33(34):4099-105. doi: 10.1200/JCO.2015.62.4726. Epub 2015 Aug 31.

17.

Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells.

Park SH, Song JY, Kim YK, Heo JH, Kang H, Kim G, An HJ, Kim TH.

Int J Oncol. 2014 Mar;44(3):637-46. doi: 10.3892/ijo.2013.2232. Epub 2013 Dec 30.

18.

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.

Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, Cecere SC, Gargiulo P, Pignata S.

Cancer Treat Rev. 2015 Feb;41(2):136-43. doi: 10.1016/j.ctrv.2014.12.003. Epub 2014 Dec 23. Review.

PMID:
25573350
19.

Low-grade serous ovarian cancer: A review.

Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod SA.

Gynecol Oncol. 2016 Nov;143(2):433-438. doi: 10.1016/j.ygyno.2016.08.320. Epub 2016 Aug 28. Review.

PMID:
27581327
20.

The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.

d'Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O'Crowley J, Haley K, Kernan N, Murphy C, Smyth PC, O'Byrne K, Pennington S, Cooke AA, Ffrench B, Martin CM, O'Donnell D, Hennessy B, Stordal B, Finn S, McCann A, Gleeson N, D'Arcy T, Flood B, O'Neill LA, Sheils O, O'Toole S, O'Leary JJ.

PLoS One. 2014 Jun 30;9(6):e100816. doi: 10.1371/journal.pone.0100816. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e108833.

Supplemental Content

Support Center